AR035008A1 - Compuestos pirimidin-2, 4, 6-trionas, su uso para la fabricacion de un medicamento y composicion farmaceutica que los comprende - Google Patents

Compuestos pirimidin-2, 4, 6-trionas, su uso para la fabricacion de un medicamento y composicion farmaceutica que los comprende

Info

Publication number
AR035008A1
AR035008A1 ARP000100594A ARP000100594A AR035008A1 AR 035008 A1 AR035008 A1 AR 035008A1 AR P000100594 A ARP000100594 A AR P000100594A AR P000100594 A ARP000100594 A AR P000100594A AR 035008 A1 AR035008 A1 AR 035008A1
Authority
AR
Argentina
Prior art keywords
cancer
substituted
trionas
compounds
manufacture
Prior art date
Application number
ARP000100594A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR035008A1 publication Critical patent/AR035008A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Los compuestos pirimidin-2,4,6-trionas de fórmula 1 donde R1 es hidrógeno, alquilo, alquilo sustituído, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituído, alcoxi, alcoxi sustituído, ariloxi o alquilalcoxi y R2 es ariloxi; las sales farmacéuticamente aceptables de un compuesto acídico de fórmula 1 y profármacos de las mismas; el uso de los mismos para la fabricación de un medicamento para el tratamiento o el control del cáncer asociado con la sobreexpresión de gelatinasa A y/o gelatinasa B, particularmente cáncer de piel, cáncer de mamas, cáncer de próstata, cáncer de colon, cáncer de pulmón y cáncer gástrico y también son útiles para otras enfermedades asociadas con la degradación no regulada de la matriz extracelular, incluyendo artritis reumatoide, osteoartritis, esclerosis múltiple, ulceración corneal, enfermedad periodontal y similares; y composición farmacéutica que los comprende.
ARP000100594A 1999-02-12 2000-02-10 Compuestos pirimidin-2, 4, 6-trionas, su uso para la fabricacion de un medicamento y composicion farmaceutica que los comprende AR035008A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11990399P 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
AR035008A1 true AR035008A1 (es) 2004-04-14

Family

ID=22387100

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100594A AR035008A1 (es) 1999-02-12 2000-02-10 Compuestos pirimidin-2, 4, 6-trionas, su uso para la fabricacion de un medicamento y composicion farmaceutica que los comprende

Country Status (16)

Country Link
US (1) US6265578B1 (es)
EP (1) EP1153015B1 (es)
JP (1) JP3655551B2 (es)
KR (1) KR100477160B1 (es)
CN (1) CN1147481C (es)
AR (1) AR035008A1 (es)
AT (1) ATE277912T1 (es)
AU (1) AU774487B2 (es)
BR (1) BR0008109A (es)
CA (1) CA2361605C (es)
DE (1) DE60014323T2 (es)
ES (1) ES2226790T3 (es)
PT (1) PT1153015E (es)
TR (1) TR200102334T2 (es)
WO (1) WO2000047565A1 (es)
ZA (1) ZA200106214B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
AP2001002318A0 (en) * 2000-10-26 2001-12-31 Pfizer Prod Inc Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
MXPA03003734A (es) 2000-10-26 2003-07-28 Pfizer Prod Inc Inhibifores de metaloproteinasa del tipo pirimidin-2, 4, 6-triona.
US6936620B2 (en) 2001-12-20 2005-08-30 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
MXPA04008563A (es) 2002-04-26 2004-12-06 Pfizer Prod Inc Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona.
MXPA04010545A (es) 2002-04-26 2005-01-25 Pfizer Prod Inc Inhibidores de metaloproteinasa de heteroariloxi-aril-espiero-pirimidina-2,4,6-triona n-sustituida.
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
JP2005529889A (ja) 2002-04-26 2005-10-06 ファイザー・プロダクツ・インク ピリミジン−２，４，６−トリオンメタロ−プロテイナーゼ阻害剤
TWI280128B (en) * 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
EP1658171B1 (en) * 2003-08-22 2008-04-30 Oerlikon Trading AG, Trübbach Method for the bonding of disk-shaped substrates and apparatus for carrying out the method
RU2400233C1 (ru) * 2009-07-07 2010-09-27 Общество с ограниченной ответственностью "Вирфарм" Способ лечения заболеваний печени различного генеза

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
ES2247707T3 (es) 1997-06-21 2006-03-01 Roche Diagnostics Gmbh Derivados del acido barbiturico con actividad antimetastasica y antitumoral.
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
EP1153015B1 (en) 2004-09-29
JP2002536439A (ja) 2002-10-29
KR100477160B1 (ko) 2005-03-17
BR0008109A (pt) 2001-11-06
CA2361605A1 (en) 2000-08-17
ATE277912T1 (de) 2004-10-15
CN1339028A (zh) 2002-03-06
KR20020011963A (ko) 2002-02-09
ZA200106214B (en) 2002-10-28
DE60014323T2 (de) 2006-02-16
JP3655551B2 (ja) 2005-06-02
US6265578B1 (en) 2001-07-24
DE60014323D1 (de) 2004-11-04
TR200102334T2 (tr) 2002-01-21
AU774487B2 (en) 2004-07-01
CN1147481C (zh) 2004-04-28
WO2000047565A1 (en) 2000-08-17
AU2908500A (en) 2000-08-29
EP1153015A1 (en) 2001-11-14
ES2226790T3 (es) 2005-04-01
PT1153015E (pt) 2004-12-31
CA2361605C (en) 2009-01-27

Similar Documents

Publication Publication Date Title
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
AR035008A1 (es) Compuestos pirimidin-2, 4, 6-trionas, su uso para la fabricacion de un medicamento y composicion farmaceutica que los comprende
ES2161290T3 (es) Derivados de quinazolina.
TR200101969T2 (tr) Enflamasyon tedavisi için sübstitüe edilmiş benzopiran analogları.
UY27981A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
GT200400076A (es) Ligandos de receptores de cannabinoides y sus usos
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
UY26782A1 (es) Derivados del benzotiazol
TW200716520A (en) 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
BR9916367A (pt) Novos compostos de bifenila e de análogos debifenila como antagonistas da integrina
AR029175A1 (es) Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
BR0314302A (pt) Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf)
UY27983A1 (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
AR006119A1 (es) Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
BRPI0418181A (pt) emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
AR050956A1 (es) Derivados de bencimidazol; sintesis de los mismos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por ligandos del receptor cb1.
ES2162916T3 (es) Derivados de acido pirimidin- o triazincarboxilico para el empleo como medicamentos.
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure